OTSU stock snapshot.
Otsuka Pakistan Limited price, fundamentals, financial report trends, and one-year performance against the KSE-100.
OTSU vs. KSE-100
Latest report-period signals.
Parsed conservatively from PSX financial report PDFs. Card values are latest report-period figures, so quarterly filings show quarterly values rather than annualized totals.
Report metrics extracted
| Stock | Trailing P/E | Price / book | ROE | Net margin | Debt / equity | Market cap | Day change |
|---|---|---|---|---|---|---|---|
OTSU Otsuka Pakistan Limited | 180.44 | 4.65 | 3.98% | 0.73% | 157.18% | PKR 5.0bn | +1.98% |
| GLAXO →GlaxoSmithKline Pakistan Limited | 10.98 | 3.03 | 29.77% | 15.21% | 48.79% | PKR 110.1bn | -0.21% |
| ABOT →Abbott Laboratories (Pakistan) Limited | 11.27 | 2.67 | 25.19% | 10.57% | 48.93% | PKR 89.8bn | +0.36% |
| HALEON →Haleon Pakistan Limited | 13.82 | 6.05 | 43.07% | 14.78% | 105.49% | PKR 88.1bn | -0.15% |
| AGP →AGP Limited | 22.65 | 3.97 | 18.27% | 11.49% | 62.09% | PKR 53.5bn | -0.20% |
Otsuka Pakistan Limited
Otsuka Pakistan Limited (the Company) was incorporated in Pakistan in the month of February 1988 as a public limited company under the repealed Companies Ordinance, 1984 ((now Companies Act, 2017 (the Act)). The Company is engaged in the manufacturing, marketing and distribution of intravenous infusions and trading in pharmaceutical products, nutritional foods and medical equipment. The Company is an indirect subsidiary of Otsuka Pharmaceutical Company Limited, Japan.
Turn OTSU from a quote into a decision trail.
PSX Clarity connects live prices, filings, dividends, and report metrics to the portfolio you actually follow.